An HIV-infected T cell. Photo courtesy of National Institutes of Health
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9. Because these immune-system cells play important roles in a wide range of diseases, from diabetes to AIDS to cancer, the achievement provides a versatile new tool for research on T cell function, as well as a path toward CRISPR/Cas9-based therapies for many serious health problems.
Using their novel approach, the scientists were able to disable a protein on the T-cell surface called CXCR4, which can be exploited by HIV when the virus infects T cells and causes AIDS. The group also successfully shut down PD-1, a protein that has attracted intense interest in the burgeoning field of cancer immunotherapy, as scientists have shown that using drugs to block PD-1 coaxes T cells to attack tumors.
The CRISPR/Cas9 system has captured the imagination of both scientists and the general public, because it makes it possible to easily and inexpensively edit genetic information in virtually any organism. T cells, which circulate in the blood, are an obvious candidate for medical applications of the technology, as these cells not only stand at the center of many disease processes, but could be easily gathered from patients, edited with CRISPR/Cas9, then returned to the body to exert therapeutic effects.
Alexander Marson, PhD
But in practice, editing T cell genomes with CRISPR/Cas9 has proved surprisingly difficult, said Alexander Marson, MD, PhD, a UCSF Sandler Fellow, and senior and co-corresponding author of the new study. “Genome editing in human T cells has been a notable challenge for the field,” Marson said. “So we spent the past year-and-a-half trying to optimize editing in functional T cells. There are a lot of potential therapeutic applications, and we want to make sure we’re driving this as hard as we can.”
The new work was done under the auspices of the Innovative Genomics Initiative (IGI), a joint UC Berkeley-UCSF program co-directed by Berkeley’s Jennifer Doudna, PhD, who is world-renowned for her pioneering research on CRISPR/Cas9, and Jonathan Weissman, PhD, professor of cellular and molecular pharmacology at UCSF and a Howard Hughes Medical Institute (HHMI) investigator. Marson is an affiliate member of the IGI.
Doudna, professor of chemistry and of cell and molecular biology at Berkeley, and an HHMI investigator, said that the research is a significant step forward in bringing the power of CRISPR/Cas9 editing to human biology and medicine. “It’s been great to be part of this exciting collaboration, and I look forward to seeing the insights from this work used to help patients in the future,” said Doudna, co-corresponding author of the new paper.
Low CRISPR Success Rate
Cas9, an enzyme in the CRISPR system that makes cuts in DNA and allows new genetic sequences to be inserted, has generally been introduced into cells using viruses or circular bits of DNA called plasmids. Then, in a separate step, a genetic construct known as single-guide RNA, which steers Cas9 to the specific spots in DNA where cuts are desired, is also placed into the cells.
Until recently, however, editing human T cells with CRISPR/Cas9 has been inefficient, with only a relatively small percentage of cells being successfully modified. And while scientists have had some success in switching off genes by inserting or deleting random sequences, they have not yet been able to use CRISPR/Cas9 to paste in (or “knock in”) specific new sequences to correct mutations in T cells.
Kathrin Schumann, PhD
As will be reported online in Proceedings of the National Academy of Sciences during the week of July 27, a team led by first authors Kathrin Schumann, PhD, a postdoctoral fellow in Marson’s laboratory, and Steven Lin, PhD, a postdoctoral fellow in the Doudna lab, cracked these problems by streamlining the delivery of Cas9 and single-guide RNA to cells.
In lab dishes, the group assembled Cas9 ribonucleoproteins, or RNPs, which combine the Cas9 protein with single-guide RNA. They then used a method known as electroporation, in which cells are briefly exposed to an electrical field that makes their membranes more permeable, to quickly deliver these RNPs to the interior of the cells.
With these innovations, the researchers successfully edited CXCR4 and PD-1, even knocking in new sequences to replace specific genetic “letters” in these proteins. The group was then able to sort the cells using markers expressed on the cell surface, to help pull out successfully edited cells for research, and eventually for therapeutic use.
“We tried for a long time to introduce Cas9 with plasmids or lentiviruses, and then to express separately the single-guide RNA in the cell,” Schumann said. “Using RNPs made outside the cell, so that the cell is responsible for as little of the process as possible, has made a big difference.”
Potential for Autoimmune Diseases and Other T Cell Disorders
Marson stressed that, while recent reports of CRISPR/Cas9 editing of human embryos have stirred up controversy, T cells are created anew in each individual, so modifications would not be passed on to future generations. He hopes that Cas9-based therapies for T cell-related disorders, which include autoimmune diseases as well as immunodeficiencies such as “bubble boy disease,” will enter the clinic in the future.
“There’s actually well-trodden ground putting modified T cells into patients. There are companies out there already doing it and figuring out the safety profile, so there’s increasing clinical infrastructure that we could potentially piggyback on as we work out more details of genome editing,” Marson said. “I think CRISPR-edited T cells will eventually go into patients, and it would be wrong not to think about the steps we need to take to get there safely and effectively.”
Other UCSF researchers participating in the study were Eric Boyer, staff research assistant; graduate students Dimitre R. Simeonov and Meena Subramaniam; research technician Rachel E. Gate; postdoctoral fellow Genevieve E. Haliburton, PhD; Chun Ye, PhD, assistant professor of epidemiology and biostatistics; and Jeffrey A. Bluestone, PhD, the A.W. and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology.
The research was supported by a gift from Jake Aronov, and by the UCSF Sandler Fellows Program; the National Institutes of Health; the National MS Society; and the Howard Hughes Medical Institute.
About the IGI
The Innovative Genomics Initiative was established in early 2014 at the Li Ka Shing Center for Genomic Engineering at the University of California, Berkeley, and is dedicated to the enhancement and proliferation of genome editing research and technology in both the academic and commercial research communities. As of 2015, the IGI and its affiliated laboratories – at UC Berkeley, UC San Francisco, and Stanford University – are actively participating in collaborations with academic and industrial research partners worldwide in order to expand our understanding and promote the use and development of CRISPR/Cas9 technology. Please visit www.innovativegenomics.org.
UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy, a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences, as well as a preeminent biomedical research enterprise and two top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospital San Francisco.